31 December 2025 As the Unified Patent Court continues in its third year, there are inevitable issues that continue to arise as it grows as a jurisdiction, writes Darren Smyth of EIP.
30 December 2025
29 December 2025
24 December 2025
24 December 2025
23 December 2025
22 December 2025
Latest Features
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Latest Conference Videos
Americas
Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.
Europe
Amanda Simons, J A Kemp, explains how clinical research affects patentability in Europe and how clinical data can be used to strengthen protection.
Biotechnology
Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.
Europe
High-value IP disputes are reshaping life sciences litigation, with perspectives from McDermott Will & Emery, Curevac, Regeneron, HGF, and the UPC.
More News
22 December 2025 Global law firm and Wall Street institution to join forces, forming one of the world’s five largest law firms by revenue and significantly expanding global and US market reach.
19 December 2025 With its landmark ruling, the court has delivered guidance for patentees and litigants— including three takeaways for counsel and rights holders, explain Tobias Wuttke and Axel Berger of Bardehle Pagenberg.
18 December 2025 A UK appellate court has revived a key patent for the tech, finding flaws in the lower court’s handling of the case and obviousness analysis over prior art.
17 December 2025 The proponents of a petition denied by the Supreme Court said it addressed a conflict that was significant “not just for the pharmaceutical industry, but for all stakeholders in our patent system”.
17 December 2025 The firm’s new hire is known for advising Boston’s biotech, pharmaceutical and chemical companies on patent strategies and commercialising scientific inventions.
16 December 2025 UK court hears claims that a delay and construction inconsistency led to the alleged wrongful invalidation of a patent at the heart of a global dispute.
15 December 2025 The proposed 1,400-strong firm will combine Taylor Wessing's top UK and European practice with Winston & Strawn's US-focused IP litigation team.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox